Last reviewed · How we verify
NCT03081702
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
Phase 1, PHASE2 trial testing Hydroxychloroquine in Platinum-resistant Epithelial Ovarian Cancer in 13 participants. Completed in 27 August 2019.
27 August 2019
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 25 July 2017 |
| Primary completion | 27 August 2019 |
| Estimated completion | 27 August 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
- Itraconazole — full drug profile →
Conditions studied
- Platinum-resistant Epithelial Ovarian Cancer — all drugs for Platinum-resistant Epithelial Ovarian Cancer →
Sponsor
University Health Network, Toronto
Who can join
18 and older, female only, with Platinum-resistant Epithelial Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase I/II study to find the highest dose of hydroxychloroquine that can be given safely with itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer. The study will also determine the safety, tolerability, and initially determine whether the combination is useful in the treatment of patients with advanced platinum-resistant epithelial ovarian cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Tavares V, Marques IS, Melo IG, Assis J, et al · · 2024 · cited 85× · PMID 38339123 · DOI 10.3390/ijms25031845 -
Chloroquine against malaria, cancers and viral diseases.
Zhou W, Wang H, Yang Y, Chen ZS, et al · · 2020 · cited 85× · PMID 32947043 · DOI 10.1016/j.drudis.2020.09.010 -
Regulation of Apoptosis by Autophagy to Enhance Cancer Therapy.
Tompkins KD, Thorburn A. · · 2019 · cited 51× · PMID 31866785 -
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006 -
The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis.
Chai JY, Sugumar V, Alshawsh MA, Wong WF, et al · · 2021 · cited 24× · PMID 34572373 · DOI 10.3390/biomedicines9091188 -
The role of autophagy in cancer: from molecular mechanism to therapeutic window.
Jalali P, Shahmoradi A, Samii A, Mazloomnejad R, et al · · 2025 · cited 22× · PMID 40248706 · DOI 10.3389/fimmu.2025.1528230 -
Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole.
Freitas RD, Dias RB, Vidal MTA, Valverde LF, et al · · 2020 · cited 17× · PMID 33312948 · DOI 10.3389/fonc.2020.563838 -
Co-targeting of lysosome and mitophagy in cancer stem cells with chloroquine analogues and antibiotics.
Al-Bari MAA. · · 2020 · cited 16× · PMID 32935427 · DOI 10.1111/jcmm.15879
Verify or expand the search:
- PubMed search for NCT03081702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydroxychloroquine
Trials testing the same drug.
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
- NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03081702 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 2 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03081702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing